Kibow Biotech, Inc

www.kibowbiotech.com

Kibow specializes in supplements for maintaining kidney health and general health and wellness and boosting immunity by restoring the intestinal microflora.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

GSK NABS SPEEDY REVIEW FOR ONE OF ITS TOP PROSPECTS

FierceBiotech | January 21, 2020

news image

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline. After seeming to turn away from oncology R&D under its old CEO Sir Andrew Witty a few years ago, new CEO and R&D head Emma Walmsley and Hal Barron, respectively, have made powering their pipeline out of the slow lane the priority. Today, GSK announced that one of its top prospects (and a drug Barron has singled out in the past) has been handed an FD...

Read More

Cell and Gene Therapy

GENSCRIPT AND GLADSTONE-UCSF INSTITUTE OF GENOMIC IMMUNOLOGY COLLABORATE ON GROUNDBREAKING NON-VIRAL CELL THERAPY STUDY

Genscript Biotech Corporation | September 23, 2022

news image

GenScript USA Inc., the world's leading life-science research tools and services provider, is collaborating with researchers at the Gladstone-UCSF Institute of Genomic Immunology to advance the development of new, non-viral cell therapies that modify genomic sequences in the pursuit of more effective cell therapy products while limiting the cellular toxicity that is typically associated with previously available methods. A new study, published in Nature Biotechnology, details ...

Read More

Industrial Impact

CALYXT ANNOUNCES PRICING OF OFFERING OF COMMON STOCK AND WARRANTS AND UPDATES BUSINESS AND RISK FACTOR DISCLOSURE

Cellectis Inc. | February 19, 2022

news image

Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. , a majority-owned subsidiary of Cellectis S.A., announced the placement to an institutional investor in an underwritten offering of (i) 3,880,000 shares of Calyxt common stock, (ii) pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and (iii) common warrants to purchase up to 7,760,000 shares of its common stock. Read More

Industrial Impact

O2 INVESTS IN MODULAR DEVICES, INC.

O2 Investment Partners ( | January 24, 2022

news image

O2 Investment Partners announced that it has partnered with Modular Devices, Inc. and its President & CEO, Greg Mink, to support the Company’s continued growth. Terms of the deal were not disclosed. Founded in 1987, Modular Devices, Inc. is a leading provider of mobile and modular medical imaging equipment labs and cleanroom solutions throughout the United States. MDI’s medical imaging solutions offer various imaging modalities through short- and long-term leases t...

Read More
news image

GSK NABS SPEEDY REVIEW FOR ONE OF ITS TOP PROSPECTS

FierceBiotech | January 21, 2020

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline. After seeming to turn away from oncology R&D under its old CEO Sir Andrew Witty a few years ago, new CEO and R&D head Emma Walmsley and Hal Barron, respectively, have made powering their pipeline out of the slow lane the priority. Today, GSK announced that one of its top prospects (and a drug Barron has singled out in the past) has been handed an FD...

Read More
news image

Cell and Gene Therapy

GENSCRIPT AND GLADSTONE-UCSF INSTITUTE OF GENOMIC IMMUNOLOGY COLLABORATE ON GROUNDBREAKING NON-VIRAL CELL THERAPY STUDY

Genscript Biotech Corporation | September 23, 2022

GenScript USA Inc., the world's leading life-science research tools and services provider, is collaborating with researchers at the Gladstone-UCSF Institute of Genomic Immunology to advance the development of new, non-viral cell therapies that modify genomic sequences in the pursuit of more effective cell therapy products while limiting the cellular toxicity that is typically associated with previously available methods. A new study, published in Nature Biotechnology, details ...

Read More
news image

Industrial Impact

CALYXT ANNOUNCES PRICING OF OFFERING OF COMMON STOCK AND WARRANTS AND UPDATES BUSINESS AND RISK FACTOR DISCLOSURE

Cellectis Inc. | February 19, 2022

Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. , a majority-owned subsidiary of Cellectis S.A., announced the placement to an institutional investor in an underwritten offering of (i) 3,880,000 shares of Calyxt common stock, (ii) pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and (iii) common warrants to purchase up to 7,760,000 shares of its common stock. Read More

news image

Industrial Impact

O2 INVESTS IN MODULAR DEVICES, INC.

O2 Investment Partners ( | January 24, 2022

O2 Investment Partners announced that it has partnered with Modular Devices, Inc. and its President & CEO, Greg Mink, to support the Company’s continued growth. Terms of the deal were not disclosed. Founded in 1987, Modular Devices, Inc. is a leading provider of mobile and modular medical imaging equipment labs and cleanroom solutions throughout the United States. MDI’s medical imaging solutions offer various imaging modalities through short- and long-term leases t...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us